Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 13/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924137 | 0.89 | PTGER1 (0.75) | PTGER1KMT2ACYP1A2CYP3A4GAA | |
| SCHEMBL4924600 | 0.86 | PTGER1 (0.74) | PTGER1KMT2ACYP1A2CYP3A4GAA | |
| SCHEMBL4771655 | 0.85 | PTGER1 (0.80) | PTGER1KMT2ACYP1A2CYP3A4GAA | |
| SCHEMBL4774737 | 0.85 | PTGER1 (0.80) | PTGER1KMT2ACYP1A2CYP3A4GAA | |
| SCHEMBL4920186 | 0.85 | PTGER1 (0.71) | PTGER1KMT2ACYP2C9ALDH1A1LMNA | |
| SCHEMBL4919404 | 0.84 | PTGER1 (0.68) | PTGER1KMT2ACYP1A2CYP3A4GAA | |
| SCHEMBL4770373 | 0.84 | PTGER1 (0.78) | PTGER1KMT2ACYP1A2CYP3A4GAA | |
| SCHEMBL4923922 | 0.83 | PTGER1 (0.70) | PTGER1CYP1A2CYP3A4GAACYP2D6 | |
| SCHEMBL4917838 | 0.83 | PTGER1 (1.00) | PTGER1KMT2ACYP1A2CYP3A4GAA | |
| SCHEMBL14008101 | 0.82 | PTGER1 (0.69) | PTGER1KMT2ACYP1A2CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | PTGER1 1/4885KMT2A 3116/4885CYP1A2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.